Pharma Journalist -

Dyne Therapeutics, a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases, launched with a $50 million Series A. Atlas Venture founded,…
Read More...

ViiV Healthcare presented three year results from the SWORD 1 & 2 studies, demonstrating that 84% (432/513) of participants who switched from their current three- or four-drug…
Read More...

Cellectis announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for…
Read More...

Clinical stage biotechnology company QUE Oncology announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot…
Read More...

BriaCell Therapeutics Corp. announced a clinical trial collaboration and supply agreement with Incyte, a global biopharmaceutical company focused on discovering and developing novel…
Read More...

Xencor, announced it has entered into a research and license agreement in which Astellas Pharma Inc. will access Xencor’s bispecific technology to advance a novel bispecific antibody…
Read More...

Novartis announced that the China Health Authority NMPA approved Cosentyx (secukinumab), the first-in-class interleukin-17A (IL-17A) inhibitor for moderate-to-severe plaque psoriasis in…
Read More...

Sangamo Therapeutics and Pfizer announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. Data indicate that SB-525…
Read More...

Pulmatrix announced its entry into a Binding Term Sheet with Cipla Technologies LLC, a subsidiary of Cipla Limited for the co-development and commercialization of Pulmazole (PUR1900) –…
Read More...

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC focused on…
Read More...